Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

Transactions / Biological Specialty Corporation

Thompson Street Capital Partners Portfolio Company BioIVT Acquires Biological Specialty Corporation

Add-on acquisitionclosedadd-onannounced Nov 5, 2018closed Nov 5, 2018Fact
What happened
Platform
BioIVTadd-on basis: Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT, a leading global provider of research models and value-added research services for drug discovery and development, has acquired Colmar, Pennsylvania-based Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community.
Control
Control
Share acquired
unknown
Industry
industrials / components
Target location
PA, US
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • BioIVTPlatformconfirmed
    Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT, a leading global provider of research models and value-added research services for drug discovery and development, has acquired Colmar, Pennsylvania-based Biological
  • Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT, a leading global provider of research models and value-added research services for drug discovery and development, has acquired Colmar, Pennsylvania-based Biological
Side not stated
  • Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT, a leading global provider of research models and value-added research services for drug discovery and development, has acquired Colmar, Pennsylvania-based Biological
Evidence
Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT, a leading global provider of research models and value-added research services for drug discovery and development, has acquired Colmar, Pennsylvania-based Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community.
Thompson Street Capital Partners Portfolio Company BioIVT Acquires Biological Specialty Co | Private Equity Intelligence | DFX